Lead Product(s) : Novolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
DynamX Bioadaptor Hong Kong Registry
Details : Novolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2020
Lead Product(s) : Novolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable